Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats

Fundarò, A; Cavalli, Roberta; Bargoni, Alessandro; Vighetto, Daniela; Zara, Gian Paolo; Gasco, Maria Rosa

doi:10.1006/phrs.2000.0695

Cited by 279 publications

(108 citation statements)

References 17 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…The lipids employed in these are usually biocompatible and biodegradable with low toxicity as opposed to the polymeric nanoparticles (Muller et al, 1996;Kumar, 2000). NLCs show high drug loading for both lipophilic and hydrophilic drugs, also promote oral absorption of encapsulated drug via selective uptake through lymphatic route or payer's patches (Fundaro et al, 2000;Chen et al, 2001). They rarely undergo blood clearance via the reticuloendothelial system (Muller et al, 2000;Kaur et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation

et al. 2016

View full text Add to dashboard Cite

The purpose of this study was to develop Carvedilol nanostructured lipid carriers (CAR-NLCs) using stearic acid and oleic acid as lipid, and to estimate the potential as oral delivery system for poorly water soluble drug. The particle-size analysis revealed that all the developed formulations were within the nanometer range. The EE and loading were found to be between 69.45-88.56% and 9.58-12.56%, respectively. The CAR-NLCopt showed spherical morphology with smooth surface under transmission electron microscope (TEM). The crystallization of the drug in NLC was investigated by powder X-ray diffraction and differential scanning calorimetry (DSC) and revealed that the drug was in an amorphous state in the NLC matrix. The ex vivo gut permeation study showed many folds increment in the permeation of CAR-NLCs compared to Carvedilol suspension (CAR-S). The oral bioavailability study of CAR was carried out using Wistar rats and relative bioavailability of CAR-NLCopt was found to be 3.95 fold increased in comparison with CAR-S. In vivo antihypertensive study in Wistar rats showed significant reduction in mean systolic BP by CAR-NLCopt vis-à-vis CAR-S (p50.05) owing to the drug absorption through lymphatic pathways. In conclusion, the NLC formulation remarkably improved the oral bioavailability of CAR and demonstrated a promising perspective for oral delivery of poorly water-soluble drugs. The promising findings in this investigation suggest the practicability of these systems for the enhancement of bioavailability of CAR.

show abstract

Section: Introductionmentioning

confidence: 99%

Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Notably, SLN's have been investigated for oral drug delivery and have been shown to exhibit good release characteristics and systemic bioavailability of the encapsulated drugs (Demirel et al 2001;Yang, et al 1999). SLN tolerability and toxicity has also been characterised in vivo (Fundarò et al 2000;Sanna et al 2004) as well as in vitro (Müller et al 1997;Mussi, et al 2013;Nassimi, et al 2010), and they are regarded to be generally well tolerated, owing to their composition from physiologically similar lipids.…”

Section: Introductionmentioning

confidence: 99%

A novel approach to oral iron delivery using ferrous sulphate loaded solid lipid nanoparticles

Zariwala

El-Said

Jackson

et al. 2013

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…In particular, all SLNs formulations significantly decreased heart and liver concentrations of doxorubicin [79]. Interestingly, both non-coated and coated SLNs showed a similar low uptake by liver and spleen macrophages [80]. The bioavailability of idarubicin can be also improved by administering idarubicin-loaded SLNs duodenally to rats.…”

Section: Anthracyclinesmentioning

confidence: 88%

Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment

Serpe

2003

Nanotechnologies for the Life Sciences

View full text Add to dashboard Cite

The sections in this article are Introduction Cancer as Drug Delivery Target Nanoparticles as Anticancer Drug Delivery System Conventional Nanoparticles Sterically Stabilized Nanoparticles Actively Targetable Nanoparticles Routes of Drug Nanoparticles Administration Anticancer Drug Nanoparticles Anthracyclines Reverse of P‐glycoprotein Mediated Multidrug Resistance of Cancer Cells to Doxorubicin Antiestrogens Anti‐metabolites Camptothecins Cisplatin Paclitaxel Miscellaneous Agents Arsenic Trioxide Butyric Acid Cystatins Diethylenetriaminepentaacetic Acid Mitoxantrone Gene Therapy

show abstract

Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats

Cited by 279 publications

References 17 publications

Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation

Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation

A novel approach to oral iron delivery using ferrous sulphate loaded solid lipid nanoparticles

Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment

Contact Info

Product

Resources

About